{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:00:33Z","timestamp":1780279233321,"version":"3.54.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["22CGA23"],"award-info":[{"award-number":["22CGA23"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["21XD1423200"],"award-info":[{"award-number":["21XD1423200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003024","name":"Shanghai Education Development Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1103900"],"award-info":[{"award-number":["2022YFA1103900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2022CRT012"],"award-info":[{"award-number":["SHDC2022CRT012"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373319"],"award-info":[{"award-number":["82373319"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141101"],"award-info":[{"award-number":["82141101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172869"],"award-info":[{"award-number":["82172869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372794"],"award-info":[{"award-number":["82372794"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtho.2024.12.022","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T22:08:05Z","timestamp":1735078085000},"page":"739-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC"],"prefix":"10.1016","volume":"20","author":[{"given":"Shiqi","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baobin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.12.022_bib1","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.022_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/PO.19.00333","article-title":"Targeting HER2 alterations in non-small-cell lung cancer: a comprehensive review","volume":"4","author":"Zhao","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","article-title":"A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer","volume":"13","author":"Hotta","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib5","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.022_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.21.01113","article-title":"Poziotinib for patients with HER2 Exon 20 mutant non-small-cell lung cancer: results from a phase II trial","volume":"40","author":"Elamin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib8","doi-asserted-by":"crossref","first-page":"S1189","DOI":"10.1016\/j.annonc.2020.08.2294","article-title":"LBA61 First analysis of RAIN-701: study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1\/ERBB gene fusions","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib9","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1200\/JCO.2021.39.15_suppl.9014","article-title":"Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1\/2 study","volume":"39","author":"Ramalingam","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib10","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.20.00297","article-title":"Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, Phase II study","volume":"38","author":"Zhou","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/annonc\/mdy542","article-title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib12","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jtho.2024.09.017","article-title":"PL04.03 safety and efficacy of BAY 2927088 in patients with HER2-mutant NSCLC: expansion cohort from the Phase I\/II SOHO-01 study","volume":"19","author":"Le","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib13","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jtho.2024.09.018","article-title":"PL04.04 primary phase Ib analysis of Beamion LUNG-1: zongertinib (BI 1810631) in patients with HER2 mutation-positive NSCLC","volume":"19","author":"Ruiter","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2024.12.022_bib15","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41591-023-02461-x","article-title":"First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial","volume":"29","author":"Liu","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.022_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-022-02245-z","article-title":"Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.jtho.2024.12.022_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-022-01226-1","article-title":"Single-cell analysis reveals the potential mechanisms of pyrotinib resistance in non-small cell lung cancer","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2024.12.022_bib18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.022_bib19","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.jtho.2024.12.022_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.jtho.2024.12.022_bib21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.21037\/tlcr-20-559","article-title":"Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations","volume":"10","author":"Yang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.022_bib22","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jtho.2020.01.020","article-title":"Conformational landscapes of HER2 Exon 20 insertions explain their sensitivity to kinase inhibitors in lung adenocarcinoma","volume":"15","author":"Zhao","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12885-018-4277-x","article-title":"Outcomes of pemetrexed-based chemotherapies in HER2-mutant lung cancers","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2024.12.022_bib24","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.jtho.2021.06.025","article-title":"Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations","volume":"16","author":"Saalfeld","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib27","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.21037\/tlcr-21-216","article-title":"Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study","volume":"10","author":"Koga","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.022_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lungcan.2018.10.019","article-title":"Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: an in vitro study","volume":"126","author":"Koga","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.12.022_bib29","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1158\/0008-5472.CAN-16-3404","article-title":"Response heterogeneity of EGFR and HER2 Exon 20 insertions to covalent EGFR and HER2 inhibitors","volume":"77","author":"Kosaka","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.022_bib30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2159-8290.CD-16-1431","article-title":"An acquired HER2T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer","volume":"7","author":"Hanker","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.022_bib31","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-22-3617","article-title":"Acquired secondary HER2 mutations enhance HER2\/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer","volume":"83","author":"Mar\u00edn","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.022_bib32","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, Phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.022_bib33","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): a targeted inhibitor of EGFR Exon 20 insertion mutants in non-small cell lung cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.022_bib34","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/0008-5472.CAN-21-1526","article-title":"Targeting HER2 Exon 20 insertion-mutant lung adenocarcinoma with a novel tyrosine kinase inhibitor mobocertinib","volume":"81","author":"Han","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.022_bib35","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T01:08:24Z","timestamp":1780276104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424025437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1556086424025437"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.022","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}